JP2022532519A5 - - Google Patents

Info

Publication number
JP2022532519A5
JP2022532519A5 JP2021565055A JP2021565055A JP2022532519A5 JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5 JP 2021565055 A JP2021565055 A JP 2021565055A JP 2021565055 A JP2021565055 A JP 2021565055A JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5
Authority
JP
Japan
Prior art keywords
sequence
composition according
antibody
lymphoma
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021565055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/062289 external-priority patent/WO2020225196A1/en
Publication of JP2022532519A publication Critical patent/JP2022532519A/ja
Publication of JP2022532519A5 publication Critical patent/JP2022532519A5/ja
Priority to JP2025166185A priority Critical patent/JP2026004466A/ja
Pending legal-status Critical Current

Links

JP2021565055A 2019-05-03 2020-05-04 限られた数のnk細胞を有する患者における抗cd19療法 Pending JP2022532519A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025166185A JP2026004466A (ja) 2019-05-03 2025-10-02 限られた数のnk細胞を有する患者における抗cd19療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19172495.4 2019-05-03
EP19172495 2019-05-03
PCT/EP2020/062289 WO2020225196A1 (en) 2019-05-03 2020-05-04 Anti-cd19 therapy in patients having a limited number of nk cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025166185A Division JP2026004466A (ja) 2019-05-03 2025-10-02 限られた数のnk細胞を有する患者における抗cd19療法

Publications (2)

Publication Number Publication Date
JP2022532519A JP2022532519A (ja) 2022-07-15
JP2022532519A5 true JP2022532519A5 (cg-RX-API-DMAC7.html) 2023-05-09

Family

ID=66647010

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565055A Pending JP2022532519A (ja) 2019-05-03 2020-05-04 限られた数のnk細胞を有する患者における抗cd19療法
JP2025166185A Pending JP2026004466A (ja) 2019-05-03 2025-10-02 限られた数のnk細胞を有する患者における抗cd19療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025166185A Pending JP2026004466A (ja) 2019-05-03 2025-10-02 限られた数のnk細胞を有する患者における抗cd19療法

Country Status (15)

Country Link
US (1) US20220242952A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962943A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532519A (cg-RX-API-DMAC7.html)
KR (1) KR20220007087A (cg-RX-API-DMAC7.html)
CN (1) CN114072424A (cg-RX-API-DMAC7.html)
AU (1) AU2020267823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137664A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193024A1 (cg-RX-API-DMAC7.html)
IL (1) IL287203A (cg-RX-API-DMAC7.html)
MA (1) MA55794A (cg-RX-API-DMAC7.html)
MX (1) MX2021013101A (cg-RX-API-DMAC7.html)
MY (1) MY209449A (cg-RX-API-DMAC7.html)
PH (1) PH12021552743A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111343TA (cg-RX-API-DMAC7.html)
WO (1) WO2020225196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes

Similar Documents

Publication Publication Date Title
Zitvogel et al. Immunological off-target effects of imatinib
Cho et al. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
US20200147084A1 (en) Tec family kinase inhibitor adjuvant therapy
JP2023517243A5 (cg-RX-API-DMAC7.html)
JP2023093495A5 (cg-RX-API-DMAC7.html)
PT1616572E (pt) Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica
JP2004512262A5 (cg-RX-API-DMAC7.html)
JP2022523740A5 (cg-RX-API-DMAC7.html)
CN107073122A (zh) 恶性肿瘤的联合治疗
JP6764017B2 (ja) がんの処置での使用のためのコビシスタット
JP2019519770A5 (cg-RX-API-DMAC7.html)
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
CN112074271A (zh) 用于治疗淋巴瘤的方法
Zic et al. The North American experience with photopheresis
JP2018535996A5 (cg-RX-API-DMAC7.html)
AU2016311136A1 (en) Combinations and uses thereof
Chou et al. Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients
WO2021124096A1 (en) Once daily cancer treatment regimen with a prmt5 inhibitor
Parisi et al. Acute myelogenous leukemia: advances and limitations of treatment
RU2013106216A (ru) Биомаркеры хронической лимфоцитарной лейкемии
Chavez et al. ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)–Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study
Pan et al. DDDR-18. SINGLE-CELL FUNCTIONAL GENOMIC ANALYSIS OF PHARMACOLOGIC RESPONSES IN NF1 MUTANT GLIOBLASTOMA REVEALS DISTINCT MECHANISMS OF ACTION FOR MEK AND SHP2 INHIBITION
Rathore et al. The chronic leukemias: current and novel therapeutic approaches
CN117279640A (zh) 使用组合疗法治疗b细胞淋巴瘤的方法
Wilson growing treatment Options for Follicular lymphoma